Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-01
1999-01-12
Lambkin, Deborah
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514315, 514249, 514259, 514265, 514274, 514312, 514418, 514588, 514617, 514627, 514671, 514690, 514720, 514723, A61K 3152, A61K 31445, A61K 31505, A61K 3108
Patent
active
058590170
ABSTRACT:
In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.
REFERENCES:
patent: 4223032 (1980-09-01), Buckle et al.
patent: 4912092 (1990-03-01), Gruber
patent: 4940782 (1990-07-01), Rup et al.
patent: 5000936 (1991-03-01), Chibret
patent: 5134119 (1992-07-01), Lezdey et al.
patent: 5354756 (1994-10-01), Underiner et al.
Burd et al., J. Exp. Med., vol. 170, pp. 245-257, "Interleukin 3-Dependent and -Independent Mast Cells stimulated with IgE And antigens Express Multiple Cytokines", Jul. 1989.
Eiseman et al., Nature, vol. 355, pp. 78-80, "Engagement of the high-affinity IgE receptor activates src protein-related tyrosine kinases", Jan. 1992.
Gauchat et al., Nature, vol. 365, pp. 340-343, "Induction of human IgE synthesis in B Cells by mast cells and basophils", Sep. 1993.
Li et al., Molecular and Cellular Biology, vol. 12, No. 7, pp. 3176-3182, "Fc.epsilon.R1 -Medicated Tyrosine Phosphorylation of Multiple Proteins, Including Phospholipase C.gamma.1 and the Receptor .beta..gamma.2 Complex, in RBL-2H3 Rat Basophilic Leukemia Cells", Jul. 1992.
Lin et al., Biochem. J., vol. 287, pp. 325-331, "Phosphatidylcholine-specific phospholipase D-derived 1,2-diacylglycerol does not initiate protein kinase C activation in the RBL 2H3 mast-cell line", 1992.
Ozawa et al., The Journal of Biological Chemistry, vol. 268, No. 3, pp. 1749-1756, "Ca.sup.2+ -dependent and Ca.sup.2+ -independent Isozymes of Protein Kinase C Mediate Exocytosis in Antigen-stimulated Rat Basophilic RBL-2H3 Cells", Jan. 1993.
Ozawa et al., The Journal of Biological Chemistry, vol. 268, No. 4, pp. 2280-2283, "Difference Isozymes of Protein Kinase C Mediate Feedback Inhibition of Phospholipase C and Stimulatory Signals for Exocytosis in Rat RBL-2H3 Cells", Feb. 1993.
Park et al., The Journal of Biological Chemistry, vol. 266, No. 36, pp. 24237-24240, "Ige-induced Tyrosine Phosphorylation of Phospholipase C-.gamma.1 in Rat Basophilic Leukemia Cells", Dec. 1991.
Plaut et al., Nature, vol. 339, pp. 64-67, "Mast cell lines produce lymphokines in response to cross-linkage of Fc.epsilon.RI or to calcium ionophores", May 1989.
White et al., The Journal of Immunology, vol. 141, No. 2, pp. 942-946, "Translocation of Protein Kinase C In Rat Basophilic Leukemia Cells Induced By Phorbol Ester Or By Aggregation of IgE Receptors", Aug. 1988.
Bursten Stuart L.
Clarke Emer
Eiseman Elisa
Singer Jack W.
Cell Therapeutics Inc.
Faciszewski Stephen
Lambkin Deborah
LandOfFree
Method for inhibiting mast cell and basophil activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting mast cell and basophil activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting mast cell and basophil activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1516269